Leukemia Research Reports最新文献

{"title":"Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights","authors":"Tatsuro Jo ,&nbsp;Takahiro Sakai ,&nbsp;Kazuhiro Noguchi ,&nbsp;Kaori Yamaguchi ,&nbsp;Kaho Umemoto ,&nbsp;Kuniko Abe ,&nbsp;Kazuto Shigematsu","doi":"10.1016/j.lrr.2026.100582","DOIUrl":"10.1016/j.lrr.2026.100582","url":null,"abstract":"<div><div>Luspatercept, an erythroid maturation agent, treats anemia in lower-risk myelodysplastic syndromes (MDS) by inhibiting SMAD2/3 signaling. However, its efficacy may be limited in immune-mediated erythroid suppression. We present two lower-risk MDS cases (per the Revised International Prognostic Scoring System) that developed red cell aplasia and poor response to luspatercept alone. Bone marrow showed near absence of erythroid precursors with multilineage dysplasia. Neither patient achieved hematologic improvement with luspatercept monotherapy. Cyclosporine A (Cy-A) was added, leading to hemoglobin improvement, transfusion independence, and marrow erythropoiesis recovery. These cases indicate red cell aplasia may reflect immune-mediated suppression, limiting luspatercept efficacy. The response to Cy-A highlights the potential role of immunosuppressive therapy. Combining luspatercept with Cy-A may offer a strategy for selected patients with lower-risk MDS and erythroid aplasia. Bone marrow reassessment should be considered in patients who fail to respond to luspatercept or who develop recurrent anemia after an initial response.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100582"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of acute leukemia during pregnancy at the National Institute of Hematology and Blood Transfusion","authors":"Bach Quoc Khanh ,&nbsp;Nguyen Hong Son ,&nbsp;Nguyen Quoc Nhat ,&nbsp;Tran Thu Thuy ,&nbsp;Nguyen Thi Mai Huong ,&nbsp;Nguyen Thu Chang ,&nbsp;Nguyen Ha Thanh","doi":"10.1016/j.lrr.2026.100595","DOIUrl":"10.1016/j.lrr.2026.100595","url":null,"abstract":"<div><div>Managing acute leukemia during pregnancy poses clinical challenges requiring a balance between maternal treatment and fetal preservation. From 2019 to 2024, 22 pregnant women were diagnosed with acute leukemia, including 7 acute lymphoblastic leukemia, 15 cases of acute myeloid leukemia, of which 1 was acute promyelocytic leukemia. Diagnosis occurred in the first, second, and third trimesters in 5, 10, and 7 patients, respectively. Nine patients elected pregnancy termination, one had a spontaneous abortion, one had intrauterine fetal demise, and three experienced concurrent maternal and fetal death. Eight patients delivered via elective cesarean section, including one twin pregnancy, resulting in 9 live births. Four neonates (including one twin pregnancy) were exposed to in utero chemotherapy, with no observed congenital anomalies. Chemotherapy was administered to 11 patients, including 3 during pregnancy, all achieving temporary disease control. These findings provide real-world data to inform the management of acute leukemia during pregnancy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100595"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148183637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","authors":"Masuho Saburi,&nbsp;Reina Nagano,&nbsp;Rika Maruyama,&nbsp;Masanori Sakata,&nbsp;Hiroyuki Takata,&nbsp;Eiichi Ohtsuka","doi":"10.1016/j.lrr.2026.100600","DOIUrl":"10.1016/j.lrr.2026.100600","url":null,"abstract":"<div><div>Blinatumomab, a CD3/CD19 bispecific T-cell engager, improves outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL), but CD19-negative relapse is an important mode of treatment failure. We report a 69-year-old woman with Philadelphia chromosome-negative B-ALL who achieved hematological complete remission after hyper-CVAD induction therapy but remained measurable residual disease (MRD)-positive. Blinatumomab was administered after one cycle of high-dose methotrexate/cytarabine, resulting in MRD negativity after one cycle. However, blinatumomab was discontinued after one cycle at the patient’s request, and hematological relapse occurred three months after MRD conversion. Relapsed blasts showed selective loss of CD19 expression, whereas cytoplasmic CD22 expression was retained. G-banding showed an apparent cytogenetic shift from a diagnostic hyperdiploid abnormal karyotype to a normal karyotype at first relapse. Inotuzumab ozogamicin induced a second hematological remission with MRD negativity, although disease control was not durable. This case highlights the importance of repeat immunophenotypic and cytogenetic assessment at relapse after blinatumomab treatment.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100600"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib-induced rhabdomyolysis: A case report","authors":"Jordan Rubenstein,&nbsp;Sarah M. Schwartz,&nbsp;Jay Vankawala,&nbsp;Michael Caplan,&nbsp;Steven Shea,&nbsp;Joseph G. Jurcic","doi":"10.1016/j.lrr.2026.100561","DOIUrl":"10.1016/j.lrr.2026.100561","url":null,"abstract":"<div><div>Imatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), is associated with myalgia and creatine kinase (CK) elevations, though severe rhabdomyolysis and myopathy are rare. We report an 83-year-old woman with CML who developed progressive proximal weakness, dark urine, and acute kidney injury after three years of imatinib therapy. Laboratory evaluation revealed CK &gt;24,000 U/L, transaminitis, and myoglobinuria. MRI showed diffuse muscle and fascial edema, while autoimmune testing was negative. Imatinib and rosuvastatin were discontinued, and the patient was managed with intravenous fluids and supportive care. CK and renal function normalized within 10 days, with substantial recovery of strength. The strong temporal relationship between drug withdrawal and improvement implicates imatinib as the etiology. This case represents one of the most severe reported instances of imatinib-induced rhabdomyolysis. Early recognition and discontinuation are essential to prevent life-threatening sequelae.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100561"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute liver failure and severe lactic acidosis as initial manifestations of primary intestinal diffuse large B-cell lymphoma: Case report","authors":"Hideki Mori ,&nbsp;Shiro Miura ,&nbsp;Momoko Soeda ,&nbsp;Yoshitaka Imaizumi","doi":"10.1016/j.lrr.2026.100574","DOIUrl":"10.1016/j.lrr.2026.100574","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) typically presents with lymphadenopathy or extranodal masses, but rarely, predominantly as scattered case reports, as acute liver failure (ALF) with severe lactic acidosis. We report a 79-year-old man who presented with fulminant ALF, leukemoid reaction, and extreme lactic acidosis. Despite intensive care, he rapidly progressed to multiorgan failure and died. Autopsy revealed primary intestinal DLBCL with diffuse hepatic infiltration. This case illustrates the diagnostic challenge in emergency settings and highlights the concept of a “metabolic catastrophe” characterized by ALF, leukemoid reaction, and lactic acidosis. Early recognition of these features should prompt consideration of invasive diagnostic procedures and suspicion for aggressive lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100574"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An indian experience","authors":"Harish Pant ,&nbsp;Ajay Gogia ,&nbsp;Atul Sharma ,&nbsp;Naveet Wig ,&nbsp;Hari Krishna Raju Sagiraju ,&nbsp;Saumyaranjan Mallick ,&nbsp;Ritu Gupta ,&nbsp;Ahitagni Biswas","doi":"10.1016/j.lrr.2025.100554","DOIUrl":"10.1016/j.lrr.2025.100554","url":null,"abstract":"<div><h3>Background</h3><div>Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) and comprises 9 % of total NHL in India. Rituximab maintenance (RM) after induction immunochemotherapy improves PFS. However, currently, no data exists from the Indian continent regarding the impact of Rituximab maintenance (RM) on overall survival (OS) &amp; progression-free survival (PFS). Our study aims to assess if RM improves the outcomes in FL patients.</div></div><div><h3>Methods</h3><div>This retrospective study included 95 patients diagnosed with FL meeting GELF criteria and registered at our institute All India Institute of Medical Sciences Delhi between January 2012 -December 2023. Among these, forty -four (46 %) patients received 2 years of RM every 2 months after induction immunochemotherapy. The primary outcome were overall survival (OS) and progression-free survival. Secondary outcomes were factors affecting OS &amp; PFS.</div></div><div><h3>Results</h3><div>Out of the 95 patients who met GELF criteria, 52 were male and 43 were female, with a median age of 53 years (range: 27–81). Advanced Ann Arbor stage III/IV comprises 82 (86 %) patients. Bone marrow involvement and bulky disease were observed in 36 (38 %) and 29 (31 %) patients respectively. Based on the Follicular Lymphoma International Prognostic Index (FLIPI-1), 27 (28 %) were low risk, 9 (10 %) intermediate risk, and 59 (62 %) were high risk. The complete remission (CR) was achieved in 71 % of patients. During follow-up, 27 (28 %) patients experienced relapsed and 8 patients transformed to diffuse large B-cell lymphoma (DLBCL). At a median follow-up of 63 months, the median OS was not reached. The median PFS was 122 months in the RM group and 94 months in the non-RM group, with 5-year PFS of 91.6 % vs 59.3 %, respectively (log-rank <em>p</em> = 0.017). Rituximab maintenance was independently associated with improved PFS (adjusted HR 0.28, 95 % CI: 0.12–0.65, <em>p</em> = 0.003). Failure to attain CR (aHR 2.49, 95 % CI: 1.20–5.19, <em>p</em> = 0.015) and bone marrow involvement (aHR 2.92, 95 % CI: 0.99–8.63, <em>p</em> = 0.05) were independently associated with inferior PFS.</div></div><div><h3>Conclusions</h3><div>Rituximab maintenance after induction immunochemotherapy significantly improved PFS. This is the first study from India demonstrating the impact of rituximab maintenance in FL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100554"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse","authors":"Donia Bouhoula ,&nbsp;Haifa Regaieg ,&nbsp;Hela Abroug ,&nbsp;Nesrine Ben Sayed ,&nbsp;Yossra Ben Youssef","doi":"10.1016/j.lrr.2025.100557","DOIUrl":"10.1016/j.lrr.2025.100557","url":null,"abstract":"<div><div>Treating pediatric acute myeloid leukemia in resource-limited settings presents unique therapeutic challenges. This study shares 19 years of experience from a Tunisian center, focusing on practical treatment outcomes. Our pediatric AML cohort (n=68) shows 50% initial remission rates (75% with idarubicin vs 31% novantrone) and 9% induction mortality. Despite salvage therapy (43% CR2), 5-year survival remained at 33%, constrained by high relapse (53%) and limited transplant access (21%). These results highlight critical needs: optimized frontline therapy and expanded salvage options for refractory cases.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100557"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells [Leukemia Research Reports 25 (2026) 100570.1-1]","authors":"Sepideh Hassanpour Khodaei,&nbsp;Shahnaz Sabetkam,&nbsp;Zeinab Mazloumi,&nbsp;Ali Rafat,&nbsp;Diana Hekari,&nbsp;Khadijeh Dizaji Asl","doi":"10.1016/j.lrr.2026.100593","DOIUrl":"10.1016/j.lrr.2026.100593","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100593"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral testicular infiltration as the initial presentation of NRAS-mutant juvenile myelomonocytic leukemia: rapid molecular remission following azacitidine and haploidentical stem cell transplantation","authors":"Yousef VatanParast","doi":"10.1016/j.lrr.2026.100601","DOIUrl":"10.1016/j.lrr.2026.100601","url":null,"abstract":"<div><h3>Background</h3><div>Juvenile myelomonocytic leukemia (JMML) rarely manifests with extramedullary involvement beyond spleen, liver, or skin; testicular infiltration at diagnosis is unreported. We describe a Novel Case of bilateral testicular leukemic infiltration as the initial presentation of NRAS-mutant JMML in a toddler, with rapid remission following azacitidine bridging and haploidentical HSCT.</div></div><div><h3>Case presentation</h3><div>A 2-year-old boy presented with pallor, abdominal distension, and bilateral scrotal swelling. Labs: leukocytosis (58 × 10⁹/L, monocytes 12.8 × 10⁹/L), anemia (Hb 8.2 g/dL), HbF 22%. BM confirmed JMML with NRAS p.G12D (VAF 42%). No pathogenic variants were detected in KRAS, PTPN11, CBL, or NF1. Conventional cytogenetic analysis demonstrated a normal male karyotype (46,XY). US: testes enlarged (18.8/18.2 mL) with hypoechoic infiltration. Azacitidine (75 mg/m²/d × 5, 2 cycles) reduced counts and size. Paternal haplo-HSCT (Flu-Treo-TT conditioning, PTCy) engrafted D + 18; testes normal at 6 weeks, molecular remission (NRAS-) at 3 months.</div></div><div><h3>Conclusions</h3><div>This novel case underscores the efficacy of azacitidine and haploidentical HSCT for NRAS-mutant JMML with testicular involvement. Routine genital examination and ultrasound are recommended for male patients.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100601"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148636631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful desensitization to bosutinib in chronic myeloid leukemia","authors":"Catarina Guedes,&nbsp;Ricardo Geraldes,&nbsp;Sara Regalo,&nbsp;Margarida Alves,&nbsp;João Lopes,&nbsp;Ana Todo-Bom,&nbsp;Carmelita Ribeiro","doi":"10.1016/j.lrr.2026.100603","DOIUrl":"10.1016/j.lrr.2026.100603","url":null,"abstract":"<div><div>Hypersensitivity reactions (HSRs) to antineoplastic agents may compromise optimal cancer treatment and lead to drug discontinuation. Although tyrosine kinase inhibitors (TKIs) are generally well tolerated, HSRs can occur, and standardized diagnostic and desensitization strategies are lacking.</div><div>We report a 69-year-old woman with chronic myeloid leukemia who developed facial and oropharyngeal angioedema nine days after starting bosutinib. Symptoms resolved after drug withdrawal, with no alternative trigger identified. As no other TKIs were tolerated and continued therapy was essential for disease control, a rapid drug desensitization protocol was designed. A 14-step, single-day inpatient protocol with incremental dosing was completed without adverse reactions. Bosutinib was then reintroduced through short stepwise dose escalation and maintained at the full therapeutic dose.</div><div>After one year, the patient remains asymptomatic, without recurrence of angioedema, and with sustained hematologic control. This is the first published desensitization protocol for bosutinib, enabling continuation of first-line therapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100603"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148940692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}